The transcriptional repressor cAMP response element modulator (CREM) ␣ has important roles in normal T cell physiology and contributes to aberrant T cell function in patients with systemic lupus erythematosus (SLE). Recently, we characterized a specificity protein-1-dependent promoter located upstream of the CREM gene that accounts for increased basal CREM expression in SLE T cells and reflects disease activity. Here, we identify a novel intronic CREM promoter (denoted P2) in front of the second exon of the CREM gene that harbors putative binding sites for TATA-binding proteins and the transcriptional activator AP-1. DNA binding studies, chromatin immunoprecipitation, and reporter assays confirmed the functional relevance of these sites, and T cell activation through CD3/CD28 stimulation or phorbol 12-myristate 13-acetate/ionomycin treatment enhances P2 promoter activity. Although the basal CREM levels are increased in T cells from SLE patients compared with healthy controls, there are remarkable differences in the regulation of CREM expression in response to T cell activation. Whereas T cells from healthy individuals display increased CREM expression after T cell activation, most likely through AP-1-dependent up-regulation of the P2 promoter, SLE T cells fail to further increase their basal CREM levels upon T cell activation due to a decreased content of the AP-1 family member c-Fos. Because CREM trans-represses c-fos transcription in SLE T cells, we propose an autoregulatory feedback mechanism between CREM and AP-1. Our findings extend the understanding of CREM gene regulation in the context of T cell activation and disclose another difference in the transcriptional machinery in SLE T cells.
The transcriptional repressor cAMP response element modulator (CREM) ␣ has important roles in normal T cell physiology and contributes to aberrant T cell function in patients with systemic lupus erythematosus (SLE). Recently, we characterized a specificity protein-1-dependent promoter located upstream of the CREM gene that accounts for increased basal CREM expression in SLE T cells and reflects disease activity. Here, we identify a novel intronic CREM promoter (denoted P2) in front of the second exon of the CREM gene that harbors putative binding sites for TATA-binding proteins and the transcriptional activator AP-1. DNA binding studies, chromatin immunoprecipitation, and reporter assays confirmed the functional relevance of these sites, and T cell activation through CD3/CD28 stimulation or phorbol 12-myristate 13-acetate/ionomycin treatment enhances P2 promoter activity. Although the basal CREM levels are increased in T cells from SLE patients compared with healthy controls, there are remarkable differences in the regulation of CREM expression in response to T cell activation. Whereas T cells from healthy individuals display increased CREM expression after T cell activation, most likely through AP-1-dependent up-regulation of the P2 promoter, SLE T cells fail to further increase their basal CREM levels upon T cell activation due to a decreased content of the AP-1 family member c-Fos. Because CREM trans-represses c-fos transcription in SLE T cells, we propose an autoregulatory feedback mechanism between CREM and AP-1. Our findings extend the understanding of CREM gene regulation in the context of T cell activation and disclose another difference in the transcriptional machinery in SLE T cells.
The cAMP response element modulator (CREM) 3 belongs to a superfamily of transcription factors, including cAMP response element (CRE)-binding protein, CREM, the inducible CRE repressor, and activating transcription factors, which are involved in numerous biologic processes, including immune cell homeostasis, steroid metabolism, and spermatogenesis (1) (2) (3) . The cAMP-mediated signaling cascade is an evolutionarily conserved pathway that comprises stimulus-dependent cAMP production, cAMP binding to the regulatory subunits of protein kinases, nuclear translocation of the regulatory units of these kinases, and phosphorylation of the CRE-binding protein/CREM/activating transcription factors. All CREM proteins are characterized by basic domain/leucine zipper motifs; however, the multiexonic character of the CREM gene, the usage of an inducible intronic promoter or alternative initiation codons, and differential splicing mechanisms account for the presence of multiple CREM isoforms that are expressed in a cell-and development-specific fashion (4 -6). Based on the specific exon composition, CREM exerts trans-activating or trans-repressive effects on target gene expression by direct binding to CREs (TGACGTCA) or the CRE 5Ј-half-site in cisregulatory regions (6). CREs are highly conserved within numerous promoters of eukaryotic genes. The ␣-isoform of CREM has been linked to decreased production of IL-2 in T cells, which was referred to as anergy (7) . We showed previously that CREM␣ interacts with the Ϫ180 site of the human IL-2 promoter and thereby represses IL-2 expression (8 -10). The identification of CREM␣ as a negative regulator of IL-2 production led to the investigation of T cells in patients with systemic lupus erythematosus (SLE), which are characterized by defective IL-2 production upon antigen stimulation (6). SLE is a chronic autoimmune disease that affects virtually every organ, including kidneys, joints, the central nervous system, and skin (11) . Elevated levels of CREM␣ in SLE T cells contribute to decreased IL-2 production and increased infection rates in SLE patients (12) . Inversely, transfection of antisense CREM␣ plasmids into SLE T cells restores IL-2 production, which ensues the ability to activate a promoter by elimination of a transcriptional repressor (9) . In addition to IL-2, further immune cell-relevant target genes that are suppressed by CREM␣ have been identified, e.g. activator protein-1 (AP-1) transcription factor c-fos, T cell receptor (TCR)/CD3, and antigen-presenting cell molecule CD86 (13) (14) (15) . The increased expression of CREM␣ in T cells from SLE patients (16) , as well as the identification of these T cell-related target genes, points to CREM␣ as a key player in orchestrating the transcriptional program of SLE T cells (11) . However, data describing how the CREM gene itself is regulated are scarce. The functional characterization of CREM promoters, as well as identification of factors that regulate their activity, is needed to understand the regulation of CREM expression in human T cells with particular relevance to SLE pathogenesis. We reported recently on a functional CREM promoter that drives CREM expression as a downstream signaling event following protein phosphatase 2A (PP2A) and specificity protein-1 (SP-1) engagement (17) . Because SLE patients show higher PP2A enzymatic activity, this CREM promoter is more active in SLE T cells and even mirrors SLE disease activity. In this study, we identified and characterized a yet unknown intronic CREM promoter in front of exon II that is activated upon T cell stimulation through AP-1 activity.
EXPERIMENTAL PROCEDURES
Study Subjects-All SLE patients included in our studies were diagnosed according to the American College of Rheumatology classification criteria (18) and were recruited from the Division of Rheumatology at the Beth Israel Deaconess Medical Center. Healthy individuals were chosen as controls. The study protocol was approved by the institutional review board, and written informed consent was obtained from all participating subjects.
Primary Total T Cell Isolation-Peripheral venous blood was collected in heparin/lithium tubes, and total human T cells were purified as described previously (17) .
Cells-Chemically competent Escherichia coli strain TOP10F (Invitrogen) was used for plasmid amplification, mutagenesis, and cloning experiments. Reporter studies were performed in primary human T cells or in a human T cell line (Jurkat clone E6-1). All cells were cultivated in RPMI 1640 medium supplemented with 10% FCS, 1% L-glutamine, and 10% penicillin/streptomycin.
Plasmids and Generation of Luciferase Reporter ConstructsExpression vectors for c-fos and c-jun (both in pcDNA3.1) were kindly provided by R. Tijan (Department of Biochemistry, University of California, Berkeley, CA), and pcDNA3.1-SP-1 was a gift of Marcin Chłystun (Institute of Medical Biochemistry, University of Münster). The CREM P2 promoter and truncated portions thereof were amplified by PCR using the RP11-134A8 human genomic clone (Sanger) as a template and primers linked to restriction sites for KpnI (forward primers) and NheI (reverse primers) as listed in Table 1 . PCR products were purified, digested with the appropriate enzymes, and ligated into precut pGL3-Basic vector (Promega). The final plasmids were sequence-verified (SeqLab, Gottingen, Germany). All plasmid DNA preparations were carried out with DNA purification kits (Genomed and Qiagen). The quantity and quality of plasmid DNA were determined by measuring the absorbance at 260 and 280 nm in a GeneQuant II RNA/DNA calculator spectrophotometer (GE Healthcare). Site-directed mutagenesis of specific protein-binding sites within the reporter constructs was performed using complementary sense and antisense DNA oligonucleotides (Eurofins MWG Operon) and PfuTurbo DNA polymerase (Stratagene) according to the manufacturers' instructions. Primer sequences for mutageneses are listed in Table 2 .
Luciferase Assays in Primary Human T Cells-Primary human T cells (3 ϫ 10 6 ) were transfected with a total amount of 3 g of reporter plasmid using the Amaxa transfection system (Lonza). Each reporter experiment included 10 ng of Renilla luciferase construct as an internal control. Five hours after transfection, cells were collected and lysed, and luciferase activity was quantified using the Dual-Luciferase assay system (Promega) according to the manufacturer's instructions. Luciferase experiments were repeated at least three times, and values in the bar graphs are given as means Ϯ S.E.
Luciferase Assays in Jurkat Cells-Polyethylenimine (Sigma) was used to perform transfection experiments in Jurkat cells (19) . We used 5 l of 0.1% polyethylenimine and 4 g of plasmid DNA per 0.75-1 ϫ 10 6 cells. Cells were kept in a polyethylenimine/DNA mixture for a total of 16 -18 h in RPMI 1640 medium supplemented with 5% FCS only. Subsequently, the medium was replaced with RPMI 1640 medium containing 10% FCS, and cells were maintained in this medium in the presence or absence of either phorbol 12-myristate 13-acetate (PMA; 50 ng/ml) and ionomycin (1 g/ml) or plate-bound anti-CD3 and anti-CD28 antibodies (each at 2 g/ml; BD Biosciences) for 24 h. Cells were harvested, and luciferase activity was measured as described above. Effector/reporter transfection experiments were performed at a molar ratio of 3:1.
mRNA Extraction, RT-PCR, and Real-time Quantitative RT-PCR-Primary human T cells (3 ϫ 10 6 ) were cultured in the presence or absence of anti-CD3 and anti-CD28 antibodies (each at 2 g/ml) for 5 h. Subsequently, total RNA was isolated using an RNeasy mini kit (Qiagen). Residual genomic DNA 
TABLE 2 Primers used for site-directed mutagenesis
The mutations introduced at the putative TATA boxes/AP-1-binding sites are underlined.
Primer Sequence
ATAAGAAAAATACAGTAGAAGTAAGATACCCTAAAAACCGTACAGGGCTTGTTTTAGCTTT contamination was removed by DNase I (Qiagen). PCR primer sequences were as follows: CREM, 5Ј-tcgcgaacttgggacga-3Ј (forward) and 5Ј-ctctacgtttatgagaatcaattacac-3Ј (reverse); IL-2, 5Ј-cactactcacagtaacctcaactcctg-3Ј (forward) and 5Ј-gtgggaagcacttaattatcaagtcagtgt-3Ј (reverse); and 18 S rRNA, 5Ј-actcaacacgggaaacctca-3Ј (forward) and 5Ј-aaccagacaaatcgctccac-3Ј (reverse). PCR products were visualized on 2% agarose gels containing ethidium bromide. Rapid Amplification of cDNA Ends (RACE)-To determine transcription start sites, we performed RACE using a GeneRacer TM kit (Invitrogen) according to the manufacturer's instructions. This technique provides a method to obtain fulllength 5Ј-ends of cDNA using known cDNA sequences from expressed sequence tags, subtracted cDNA, differential display, or library screening and ensures the amplification of full-length transcripts only by elimination of truncated messages from the amplification process. It results in selective ligation of an RNA oligonucleotide to the 5Ј-ends of decapped mRNA using T4 RNA ligase. For RACE experiments, total RNA from Jurkat cells was isolated using the RNeasy kit.
EMSA-Nucleoprotein lysates were prepared from total T cells from healthy blood donors as described previously (17) . A double-stranded DNA probe harboring the AP-1 site (Ϫ264/ Ϫ258; 5Ј-gtaagattgacaaaaaaccgtacag-3Ј) within the CREM P2 promoter was radiolabeled using T4 polynucleotide kinase and [␥-
32 P]ATP. Binding reactions were performed at room temperature for 20 min in Hi-Density Tris borate/EDTA binding buffer (Invitrogen) containing 5 g of nuclear protein from primary human T cells obtained from healthy blood donors and 1 g of poly(dI)-poly(dC) in a total volume of 20 l. Electrophoresis and autoradiography were performed as described previously (17) . For supershift assays, 2 g of anti-c-Fos monoclonal antibody (Santa Cruz Biotechnology) was added to the binding reaction. 50-and 100-fold molar excesses of unlabeled oligonucleotide and an unrelated competitor (5Ј-agagccgagaccacgccactgcagtttagcttggacagag-3Ј) were used for competition assays.
ChIP Assay-Primary human T cells were cultivated in the presence or absence of anti-CD3 and anti-CD28 antibodies (each at 2 g/ml) for 5 h. Subsequently, cells were fixed in 1% formaldehyde for 10 min, lysed, and sonicated. ChIP analysis was performed using a ChIP assay kit (Millipore) according to the manufacturer's instructions at 2 ϫ 10 6 cells/immunoprecipitating antibody. The DNA-protein complexes were immunoprecipitated with either anti-c-Fos polyclonal antibody (Santa Cruz Biotechnology) or an isotype-matched control antibody (Santa Cruz Biotechnology), subjected to a series of washing steps, and reverse-cross-linked, and the protein was digested with proteinase K (Qiagen). DNA was extracted using a QIAamp DNA mini kit (Qiagen). Immunoprecipitated and purified DNA was analyzed by real-time quantitative PCR using the following primers, detecting the relevant sequence of the CREM P2 promoter: 5Ј-gatagcactgctttctcttc-3Ј (forward) and 5Ј-gggagatcgtaacatttcac-3Ј (reverse). The corresponding input DNA (20%) was analyzed by the same method, and immunoprecipitated DNA was calculated as percentage of input DNA.
Statistical Analysis-Student's paired two-tailed t test was used for statistical analysis. Data were considered statistically significant at p Ͻ 0.05 and p Ͻ 0.01.
RESULTS

A Second CREM Promoter Is Active in Human T Cells-To
analyze T cell activation-dependent regulation of CREM␣ expression, we stimulated total T cells obtained from SLE patients and healthy individuals with anti-CD3 and anti-CD28 antibodies for 5 h and analyzed CREM␣ expression at the messenger level using primers targeting the CREM␣ N terminus (Fig. 1A) . Of note, activation led to a decreased amount of CREM␣ mRNA in SLE T cells, whereas it was increased in control T cells. We also analyzed IL-2 mRNA from these samples and found elevated levels in both healthy and SLE T cells upon activation. However, in line with previous data, IL-2 levels displayed a far lower increase in activated SLE T cells compared with activated T cells from healthy donors. Most likely, the ultimate IL-2 production following T cell activation may not be directed by CREM␣ alone, but rather by a complex interplay between multiple activation-induced transcription factors that mediate IL-2 transcription (e.g. NF-AT (nuclear factor of activated T cells) and NF-B (19)). Furthermore, CD28 co-stimulation is known to contribute to increased IL-2 mRNA stability (20) . Thus, the ultimate IL-2 expression results may not be explained by CREM␣-mediated effects alone.
Genomatix analysis of the CREM promoter that we published previously did not define any binding sites for major transcription factors that are activated by CD3/CD28 stimulation, such as AP-1 or NF-AT. This led us to predict the presence of a yet unknown promoter region that mediates differential CREM␣ expression in SLE and normal T cells following TCR activation.
We used two different approaches to identify putative promoter regions within the human CREM gene on chromosome 10. First, we screened 30,000 bp upstream of the previously published start codon of the CREM gene using ElDorado Gene2Promoter software (Genomatix) (21) . This tagged two putative promoters (Fig. 1B) located 21 kb (denoted P1, in front of exon I) and 10 kb (denoted P2, in front of exon II) upstream of the start codon. Whereas P1 corresponds to the SP-1-dependent CREM promoter that we characterized previously (17), P2 has not been described yet. However, a MEDLINE search revealed that the 3Ј-ends of both promoters have been already identified as transcription initiation sites in different cell systems without any further characterization (22) .
Second, we performed RACE analysis using RNA from stimulated human T cells to identify transcription initiation sites within the CREM gene. This technique confirmed the transcription initiation site located 21 kb upstream of the start codon (Fig. 1B) . Although RACE analysis did not affirm the transcription initiation site located 10 kb upstream of the start codon, cDNA analysis of human T cells with selective primers for exon II showed that this part is actively transcribed and induced after stimulation (data not shown). We constructed luciferase reporter plasmids of the P2 promoter and truncated forms thereof to analyze their responsiveness to T cell activation and to decipher the underlying transcriptional machinery.
CREM P2 Promoter Is Regulated by TATA Elements and AP-1-Reporter constructs of the CREM P2 promoter were transfected into Jurkat cells and tested for their promoter activities at the basal level or after anti-CD3/CD28 antibody or PMA/ionomycin stimulation for 24 h (Fig. 2) . In line with other promoter identification studies, P2 promoter plasmids displayed variable activity levels depending on their size, which supports the existence of multiple transcriptional activators and repressors that mediate the ultimate promoter activity. Whereas the reporter construct spanning the proximal 200 bp of the P2 promoter did not display enhanced promoter activity upon CD3/CD28 or PMA/ionomycin stimulation, these stimulations led to a robust 2-3-fold increase in the reporters containing longer portions of the P2 promoter (500, 800, and 1193 bp, respectively). Of note, T cell activation showed a less pronounced effect on the P1 promoter (data not shown). In contrast to P1, the P2 promoter contains two TATA boxes, which both appear to be necessary for full promoter activity because site-directed mutagenesis of either one decreased both basal and stimulation-induced promoter activities (Fig. 3A) . To unravel the activation-induced increase in P2 promoter activity, we screened for cis-regulatory elements within the proximal 500 bp of P2 and were able to map a putative AP-1-binding site located between 264 and 258 bp upstream of the start codon (Fig. 1C) , which shows high homology to AP-1-binding sites within other promoters, such as matrix metalloproteinase-9 and IL-6 (23, 24) . Co-transfection experiments with AP-1 proteins c-Fos and c-Jun enhanced promoter activity by 2-4-fold depending on the promoter length (Fig. 3B) . Mutation of this AP-1 site (Ϫ268/Ϫ258) resulted in decreased P2 activity at the basal level as well as upon T cell activation with PMA and ionomycin to enhance promoter activity (Fig. 3C) . DNA binding studies using nucleoprotein lysates obtained from Jurkat cells and a double-stranded oligonucleotide spanning this site confirmed AP-1 binding to this site. Both supershift assays with anti-Fos monoclonal antibody and competition assays that included the unlabeled oligonucleotide at a 50-or 100-fold molar excess significantly decreased the band intensity of a specific DNA-protein complex (Fig. 3, D and E) . ChIP analyses in primary human T cells that were cultivated in the presence or absence of anti-CD3 and anti-CD28 antibodies confirmed significantly increased in vivo c-Fos binding to the AP-1 site (Ϫ264/Ϫ258) within the P2 promoter following T cell activation (36.11 Ϯ 10.66 versus 3.18 Ϯ 0.22 in unstimulated cells; p ϭ 0.025) (Fig. 3F) .
P2 Promoter Activation Is Defective in SLE T Cells-CREM␣ has been shown to be a negative regulator of c-fos gene transcription that contributes to decreased c-fos expression in SLE T cells (13) . Because the activity of the CREM P2 promoter is regulated by AP-1, an autoregulatory feedback mechanism between AP-1 and CREM is very likely and may explain the differences in the responsiveness of SLE and normal T cells to transcribe the CREM gene following T cell activation. We therefore transfected P2 promoter constructs P2-300, P2-500, and P2-800 (all of them harboring the AP-1 site (Ϫ264/Ϫ258) that we characterized beforehand) into primary T cells obtained from SLE patients and healthy controls (Fig. 4) . Whereas SLE T cells did not show any enhanced basal P2 promoter activity (relative to the empty pGL3 vector), the promoter activity in normal T cells increased by 1.7-and 2.2-fold. The fact that the difference between SLE and normal T cells in terms of P2 promoter activity reaches statistical significance suggests the existence of yet another transcriptional aberration in SLE T cells (Fig. 5) . Of note, P2 activity in SLE and healthy T cells displays an "opposite behavior" compared with P1 activity, which is consistently higher in SLE T cells and even mirrors SLE disease activity (17) .
DISCUSSION
We reported previously that, in SLE T cells, the overexpressed PP2A dephosphorylates SP-1, which drives increased expression of CREM through the CREM P1 promoter (17) . In this study, we have presented evidence of the presence of yet another CREM promoter (P2) located upstream of exon II that accounts for the increased expression of CREM in normal T cells following activation. Specifically, the P2 promoter (i) is regulated independently by a different subset of transcription factors compared with P1, (ii) is responsive to T cell activation by either CD3/CD28 or PMA/ionomycin stimulation, and (iii) displays significantly decreased activity in T cells from SLE patients. Whereas P1 is a TATA-less promoter, P2 contains two well defined TATA boxes and an AP-1 site, all of which are FIGURE 3. P2 promoter is regulated through TATA boxes and AP-1 activity. A, site-directed mutagenesis of both of the putative TATA sites within the P2 promoter was performed, and non-mutated as well as mutated constructs were transfected into Jurkat T cells to analyze promoter activity at the basal level (white bars) and following stimulation with PMA/ionomycin (Iono; black bars). The experiment was repeated five times, and values are given as means Ϯ S.D. B, P2 reporter constructs were co-transfected with either c-fos/c-jun expression plasmids (black bars) or an empty vector (white bars), and luciferase activity was measured. The experiment was repeated five times, and values are given as means Ϯ S.D. C, the AP-1 site (Ϫ264/Ϫ258) within the P2 promoter was mutated (mAP-1), and the promoter activities of the wild-type promoter and the mutant were analyzed in the absence (white bars) and presence (black bars) of PMA/ionomycin for 24 h. The experiment was repeated five times, and values are given as means Ϯ S.D. D, EMSA was performed using a radiolabeled oligonucleotide harboring the AP-1 site (Ϫ264/Ϫ258), nucleoprotein from primary human T cells, and anti-c-Fos antibody. E, competition assays were performed using either the unlabeled probe or an unrelated oligonucleotide (without any AP-1 sites) at a 50-or 100-fold molar excess, respectively. functional and contribute to activation-induced CREM␣ expression in normal T cells. SLE T cells express increased levels of the transcriptional repressor CREM␣, which is known to interact with the proximal promoter of the AP-1 family member c-Fos and to repress c-fos transcription. Previous data from our group substantiate that T cell activation leads to significantly decreased c-Fos levels in SLE cells compared with activated T cells from healthy individuals at both the mRNA and protein levels; furthermore, post-stimulation c-fos mRNA amounts correlate inversely to SLE disease activity (13) . Altogether, these findings point to an autoregulatory loop between CREM␣ and AP-1 activities that accounts for the aberrant activation-induced CREM␣ expression in SLE T cells. Whereas AP-1 regulates P2 activity, P1 does not define any AP-1 consensus sites, and forced c-fos/ c-jun expression did not affect P1 promoter activity (data not shown). Conversely, there are no putative SP-1 sites present in P2, which points to the fact that both promoters act independently as they require different transcriptional regulators that are induced under various physiologic and/or pathologic conditions. TCR engagement initiates a signaling cascade that comprises phosphorylation of the TCR/CD3 -chain, activation of ZAP-70 (zeta-chain-associated protein 70), increases in the intracellular calcium levels, and activation of cytoplasmic protein kinases, such as PKC, calcineurin, JNKs, and MAPK/ERK kinases (1, 25) . Eventually, these kinases catalyze phosphorylation of effector proteins, e.g. transcription factors NF-AT, AP-1, and NF-B. The AP-1 family member c-Jun is phosphorylated and thereby activated through PKC and JNK (28) . Upon activation, c-Jun enters the nucleus and forms homo-or heterodimers with newly transcribed and produced c-Fos proteins (26) . These protein complexes are known to interact with AP-1 sites within cis-regulatory gene regions with even increased binding affinity if the AP-1 complex cooperates with other transcription factors like NF-AT (25) (26) (27) . Both c-Fos and c-Jun are potent trans-activators, and their binding to the IL-2 promoter is an essential prerequisite for IL-2 transcription.
In contrast, the transcription factor SP-1 needs to be dephosphorylated, e.g. through PP2A, to exert its transcriptional activity (17, 28) . We have demonstrated that PP2A-mediated dephosphorylation at SP-1 serine 59 is critical for CREM P1 promoter activity in SLE T cells. Expression of both IL-2 and the IL-2 receptor gene has been shown to be regulated by an interplay between AP-1 and SP-1 that eventually mediates cell cycle progression and T cell proliferation (24, 27) . Here, we have provided evidence that also the human CREM gene comprises cis-regulatory targets for these two transcription factors.
So far, CREM activation and its functional propensities to act as a suppressor or activator of gene transcription have been explained mainly by post-transcriptional mechanisms, such as alternative splicing and protein phosphorylation/dephosphorylation, e.g. through PKA, PKC, MAPKs, and calcium/calmodulin-dependent kinases IV and II (6, 10, 30, 31). Until now, four functional promoters have been characterized that regulate expression of different truncated CREM isoforms at the transcriptional level: the P1 promoter, which drives the constitutive activation of CREM␣; a promoter that regulates expression of the short inducible CRE repressor variant of CREM; and two more (termed P3 and P4) that account for increased expression of activating CREM isoforms in spermatocytes (32) . The inducible CRE repressor isoform contains only the DNA-binding domain, is rapidly up-regulated after T cell activation, and suppresses IL-2 transcription (33). However, the production and transcriptional activities of CREM␣, which is the most abundant full-length CREM isoform in T cells, contribute to a sustained and prolonged IL-2 down-regulation in SLE T cells. Both CREM P1 and P2 promoters regulate transcription and expression of the full-length CREM isoforms, and our findings do not clarify whether one of the two determines transcription of specific CREM isoforms. However, the particular characteristics of these promoters, as well as the different expression and activity levels of AP-1 and SP-1, contribute to the differential "behavior" of P1 and P2 in SLE and normal T cells.
Because CREM␣ controls the expression of multiple genes that orchestrate the immune response, including IL-2 and c-fos/AP-1, the identification and functional characterization of the CREM P1 and P2 promoters advance our understanding of the regulation of CREM expression in health and disease. Although, in normal T cells, CREM␣ expression increases only after stimulation, in time to curb IL-2 production, and limits the length of the response, in SLE T cells, CREM␣ expression is increased prior to in vitro stimulation and contributes to suppressed IL-2 production. It is possible that the recorded increase in CREM␣ expression in normal T cells represents an in vivo stimulation of T cells by autoantigens and/or circulating anti-CD3/TCR antibodies. The increased expression of CREM␣ contributes to the suppression of c-fos/AP-1, a transcriptional activator of several immune response genes, such as IL-2 and IL-6. The data presented in this study clearly reveal the complex mechanisms that control the expression of CREM␣ and its target genes. It appears that the increased basal CREM␣ expression in SLE T cells and its subsequent failure to increase after stimulation result in an apparent immune dysregulation. If CREM␣ expression were to be "silenced" in SLE T cells, it would permit normal expression of IL-2 and c-fos/AP-1 and timely termination of the (auto)immune response.
